Psychedelic stocks mixed as FDA comments on MDMA therapy (update)

Grandbrothers/iStock Editorial via Getty Images

Update 2.05 PM EST: Adds comments from Jefferies

Companies focused on psychedelic medicines indicated a mixed performance on Friday after the U.S. FDA commented on Lykos Therapeutics' marketing application for midomafetamine (MDMA), also known as ecstasy, ahead of an advisory committee meeting on the drug.